211 related articles for article (PubMed ID: 33990489)
1. Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide.
Johnson KA; Okochi H; Glidden DV; Gandhi M; Spinelli M
J Acquir Immune Defic Syndr; 2021 Sep; 88(1):57-60. PubMed ID: 33990489
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Salama E; Hill L; Patel N; Best BM; Momper JD
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):389-392. PubMed ID: 34285156
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
Hill A; Hughes SL; Gotham D; Pozniak AL
J Virus Erad; 2018 Apr; 4(2):72-79. PubMed ID: 29682298
[TBL] [Abstract][Full Text] [Related]
5. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
6. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
[No Abstract] [Full Text] [Related]
7. Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis.
Massih SA; Atta MG; Thio CL; Tornheim JA; Fuchs EJ; Bakshi RP; Marzinke MA; Hendrix CW; Weld ED
AIDS Res Ther; 2024 May; 21(1):34. PubMed ID: 38773606
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials.
Pilkington V; Hughes SL; Pepperrell T; McCann K; Gotham D; Pozniak AL; Hill A
AIDS; 2020 Dec; 34(15):2259-2268. PubMed ID: 33048869
[TBL] [Abstract][Full Text] [Related]
10. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
[TBL] [Abstract][Full Text] [Related]
11. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
Post FA; Yazdanpanah Y; Schembri G; Lazzarin A; Reynes J; Maggiolo F; Yan M; Abram ME; Tran-Muchowski C; Cheng A; Rhee MS
HIV Clin Trials; 2017 May; 18(3):135-140. PubMed ID: 28303753
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
14. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
15. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
16. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Kayes T; Crane H; Symonds A; Dumond J; Cottrell M; Di Girolamo J; Manandhar S; Lim TH; Gane E; Kashuba A; Levy MT
Aliment Pharmacol Ther; 2022 Aug; 56(3):510-518. PubMed ID: 35599363
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
Bukkems VE; Necsoi C; Hidalgo Tenorio C; Garcia C; Alba Alejandre I; Weiss F; Lambert JS; van Hulzen A; Richel O; Te Brake LHM; van der Meulen E; Burger D; Konopnicki D; Colbers A
Clin Infect Dis; 2022 Sep; 75(4):623-629. PubMed ID: 34864950
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
[TBL] [Abstract][Full Text] [Related]
19. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Huhn GD; Eron JJ; Girard PM; Orkin C; Molina JM; DeJesus E; Petrovic R; Luo D; Van Landuyt E; Lathouwers E; Nettles RE; Brown K; Wong EY
AIDS Res Ther; 2019 Aug; 16(1):23. PubMed ID: 31464642
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).
Coyle RP; Morrow M; Mann SC; Mainella V; Ellis SL; Schwab S; Coppinger C; Barker N; Ellison L; Zheng JH; Al Zuabi S; Alpert PE; Carnes TC; Buffkin DE; Chai PR; Bushman LR; Kiser JJ; MaWhinney S; Brooks KM; Anderson PL; Castillo-Mancilla JR
Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38636950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
